Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients
Titel:
Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients
Auteur:
Mapuskar, K.A. Vasquez Martinez, G. Pulliam, C.F. Petronek, M.S. Steinbach, E.J. Monga, V. Furqan, M. Jetton, J.G. Saunders, D.P. Pearce, A. Davidson, S. Pitre, L. Dunlap, N.E. Fairbanks, R. Lee, C.M. Mott, S.L. Bodeker, K.L. Cl, Huang Buatti, J.M. Anderson, C.M. Beardsley, R.A. Holmlund, J.T. Zepeda-Orozco, D. Spitz, D.R. Allen, B.G.